The Roche partnership provides a strong validation of Zymeworks' TriTCE platform and a meaningful cash infusion. Traders should watch for HSR clearance timing and the Phase 1b initiation trigger for the $40M milestone. The deal de-risks ZW209 development and could lead to further partnership interest in Zymeworks' pipeline.
Price Chart
Executive Summary
Zymeworks entered into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks receives a $55 million upfront payment (due after HSR clearance) and a $40 million milestone upon Phase 1b initiation, with up to $718 million in additional milestones and tiered high-single-digit to mid-teen royalties. Roche funds the Phase 1a trial and takes over global development and commercialization, validating Zymeworks' platform and providing near-term cash.
Key Financial Metrics
Key Facts
- Upfront payment of $55.0 million due after HSR clearance
- Milestone payment of $40.0 million upon Phase 1b initiation
- Up to $718 million in additional development, commercial, and sales-based milestones
- Tiered high-single-digit to mid-teen royalties on global net sales
- Roche funds Phase 1a monotherapy trial and is responsible for all subsequent development and commercialization
- U.S. FDA IND clearance already received; Phase 1 study initiated
- Transaction subject to HSR clearance and other customary conditions
Financial Impact
Zymeworks receives $55M upfront + $40M near-term milestone + up to $718M in milestones + tiered royalties; total potential deal value exceeds $813M in upfront and milestones alone
Risk Factors
- HSR clearance may be delayed or not obtained, preventing deal close
- Phase 1a/1b clinical data may fail to replicate preclinical results
- Roche can terminate the agreement at will with written notice
- Milestone and royalty payments are contingent on successful development and commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001937653-26-000055 |
| Document: finalpr.htm | 0001937653-26-000055 |
| Document: 0001937653-26-000055-index-headers.html | 0001937653-26-000055 |
| Document: 0001937653-26-000055-index.html | 0001937653-26-000055 |
| Document: 0001937653-26-000055.txt | 0001937653-26-000055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEFA14A | $28.23 | awaiting T+1 | — | $28.85 (+2.20%) |
Oct 26, 2026 1d ago | DEF 14A | $28.37 | awaiting T+1 | — | $28.85 (+1.69%) |
Oct 23, 2026 4d ago | 8-K | $28.22 $28.37 | ▲ +0.53% | ▼ −0.18% | $28.85 (+2.23%) |
Oct 15, 2026 12d ago | Press Release | $25.75 $25.03 | ▼ −2.80% | ▼ −1.69% | $28.85 (+12.04%) |
Oct 9, 2026 18d ago | 144 | $25.79 $25.33 | ▼ −1.78% | ▼ −1.72% | $28.85 (+11.87%) |
Sep 28, 2026 29d ago | Press Release | $27.12 $27.20 | ▲ +0.29% | ▲ +0.48% | $28.85 (+6.38%) |
Sep 23, 2026 4w ago | Press Release | $26.81 $26.52 | ▼ −1.08% | ▼ −1.63% | $28.85 (+7.61%) |
Aug 25, 2026 9w ago | 8-K | $27.47 $29.31 | ▲ +6.68% | ▲ +6.66% | $28.85 (+5.02%) |
Jul 16, 2026 14w ago | Press Release | $24.19 | awaiting T+1 | — | $28.85 (+19.26%) |
Jun 29, 2026 17w ago | Press Release | $24.10 $26.14 | ▲ +8.46% | ▲ +7.69% | $28.85 (+19.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers